抗てんかん薬の世界市場2016-2020

◆英語タイトル:Global Epilepsy Drugs Market 2016-2020
◆商品コード:IRTNTR8891
◆発行会社(調査会社):Technavio
◆発行日:2016年7月5日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、抗てんかん薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、抗てんかん薬の世界市場規模及び予測、種類別分析、てんかん発作別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About the Epilepsy Drugs Market
Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.
Etiology
Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder.

Technavio’s analysts forecast the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global epilepsy drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent epilepsy and related seizures. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Epilepsy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Eisai
• GSK
• Pfizer
• UCB

[Other prominent vendors]
• AbbVie
• Acorda Therapeutics
• Alexza Pharmaceuticals
• Aprecia Pharmaceuticals
• Aurobindo Pharma
• Biscayne Pharmaceuticals
• CURx Pharmaceuticals
• Dainippon Sumitomo Pharma
• D-Pharm
• F. Hoffmann-La Roche
• Grupo Ferrer Internacional
• GW Pharmaceuticals
• Insero Health
• INSYS Therapeutics
• Janssen Pharmaceuticals
• Ligand Pharmaceuticals
• H. Lundbeck
• MarcoPolo Pharmaceuticals
• Marinus Pharmaceuticals
• Meda
• Neurelis
• Nobelpharma
• Novartis
• Orphelia Pharma
• SAGE Therapeutics
• SciFlour
• Sedor Pharmaceuticals
• Shire
• SK Biopharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals (US)
• Supernus Pharmaceuticals
• Takeda
• Turing Pharmaceuticals
• Upsher-Smith
• Valeant Pharmaceutical
• Zogenix

[Market driver]
• Tentative approval of late-stage pipeline molecules
• For a full, detailed list, view our report

[Market challenge]
• Social stigma associated with epilepsy
• For a full, detailed list, view our report

[Market trend]
• Reformulation of marketed drugs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Epilepsy: An overview

PART 05: Pipeline analysis

PART 06: Key buying criteria for anti-epileptic drugs

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by generation of drugs
• First-generation anti-epileptic drugs
• Second-generation anti-epileptic drugs
• Third-generation anti-epileptic drugs

PART 09: Market segmentation by spectrum of activity
• Narrow-spectrum anti-epileptic drugs
• Broad-spectrum anti-epileptic drugs

PART 10: Market segmentation by type of seizures
• Partial onset seizures
• Generalized seizures

PART 11: Geographical segmentation
• Global epilepsy drugs market by geography 2016-2020
• Epilepsy drugs market in Americas
• Epilepsy drugs market in US
• Epilepsy drugs market in EMEA
• Epilepsy drugs market in APAC
• Epilepsy drugs market in Japan
• Epilepsy drugs market in Australia
• Epilepsy drugs market in China
• Epilepsy drugs market in India

PART 12: Market drivers
• Tentative approval of late-stage pipeline molecules
• Special regulatory designations
• Development of novel therapeutics using innovative technologies

PART 13: Impact of drivers

PART 14: Market challenges
• Social stigma associated with epilepsy
• Growing use of seizure management devices is a threat to drug therapies
• Gradual decrease in incentives/investment by vendors for new drug development

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Development of devices and smartphone apps to detect seizures and track medications
• Reformulation of marketed drugs
• Increased uptake of new-generation drugs

PART 17: Vendor landscape
• Competitive scenario
• Key news

PART 18: Key vendor analysis
• Eisai
• GSK
• Pfizer
• UCB
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Pipeline portfolio: Epilepsy drugs
Exhibit 03: Percentage share of pipeline molecules for global epilepsy drugs market
Exhibit 04: Key buying criteria for anti-epileptic drugs
Exhibit 05: Global epilepsy drugs market snapshot: Developed and emerging markets 2015
Exhibit 06: Global epilepsy drugs market 2015-2020 ($ billions)
Exhibit 07: A few research studies targeting cause of epilepsy
Exhibit 08: Segmentation of marketed anti-epileptic drugs based on mechanism of action
Exhibit 09: Five forces analysis
Exhibit 10: Timeline of development of anti-epileptic drugs
Exhibit 11: Segmentation of global anti-epileptic drugs market based on generation of drugs 2015
Exhibit 12: Opportunity analysis of global epilepsy drugs market by generation of drugs
Exhibit 13: Segmentation of global epilepsy drugs market by the spectrum of activity of drugs 2015
Exhibit 14: Segmentation of global epilepsy drugs market based on type of seizures
Exhibit 15: Global epilepsy drugs market by geography 2015-2020
Exhibit 16: Global epilepsy drugs market by geography 2015 and 2020
Exhibit 17: Global epilepsy drugs market by geography 2015-2020 ($ billions)
Exhibit 18: Epilepsy drugs market in Americas 2015-2020 ($ billions)
Exhibit 19: Epilepsy drugs market in Americas by geography 2015
Exhibit 20: Comparison of US healthcare system: Before and after reforms
Exhibit 21: Epilepsy drugs market in US 2015-2020 ($ billions)
Exhibit 22: Epilepsy drugs market in EMEA by geography 2015
Exhibit 23: Epilepsy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 24: Epilepsy drugs market in APAC 2015-2020 ($ billions)
Exhibit 25: Epilepsy drugs market in APAC by geography 2015
Exhibit 26: Epilepsy drugs market in Japan 2015-2020 ($ millions)
Exhibit 27: Epilepsy drugs market in Australia 2015-2020 ($ millions)
Exhibit 28: Epilepsy drugs market in China 2015-2020 ($ millions)
Exhibit 29: Epilepsy drugs market in India 2015-2020 ($ millions)
Exhibit 30: Impact of drivers
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Position of key vendors in global epilepsy drugs market 2015
Exhibit 33: Geographical presence of key vendors
Exhibit 34: Company portfolio analysis in global epilepsy drugs market 2016-2020
Exhibit 35: Eisai: YoY revenue and growth rate of Fycompa (Americas and EMEA) 2013-2015 ($ millions)
Exhibit 36: Eisai: YoY revenue and growth rate of Zonegran (EMEA) 2013-2015 ($ millions)
Exhibit 37: Eisai: YoY revenue and growth rate of Banzel (Americas and EMEA) 2013-2015 ($ millions)
Exhibit 38: Eisai: YoY revenue and growth rate of Zebinix (EMEA) 2013-2015 ($ millions)
Exhibit 39: Eisai: Metrics analysis
Exhibit 40: GSK: YoY revenue and growth rate of Lamictal 2013-2015 ($ millions)
Exhibit 41: GSK: Metrics analysis
Exhibit 42: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 43: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 44: Pfizer: Metrics analysis
Exhibit 45: UCB: YoY revenue and growth rate of Keppra 2013-2015 ($ millions)
Exhibit 46: UCB: Geographical segmentation of Keppra by revenue 2015
Exhibit 47: UCB: YoY revenue and growth rate of Vimpat 2013-2015 ($ millions)
Exhibit 48: UCB: Geographical segmentation of Keppra by revenue 2015
Exhibit 49: UCB: Metrics analysis



【掲載企業】

Eisai, GSK, Pfizer, UCB, Acorda Therapeutics, Alexza Pharmaceuticals, Aprecia Pharmaceuticals, Aurobindo Pharma, Biscayne Pharmaceuticals, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, D-Pharm, F. Hoffmann-La Roche, Grupo Ferrer Internacional, GW Pharmaceuticals, Insero Health, INSYS Therapeutics, Janssen Pharmaceuticals, Ligand Pharmaceuticals, H. Lundbeck, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda, Neurelis, Nobelpharma, Novartis, Orphelia Pharma, SAGE Therapeutics, SciFlour, Sedpr Pharmaceuticals, Shire, SK Biopharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals (US), Supernus Pharmaceuticals, Takeda, Turing Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals, Zogenix.

【レポートのキーワード】

抗てんかん薬、てんかん発作、てんかん治療薬、医薬品、全般発作

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[抗てんかん薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[抗てんかん薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆